Novo Nordisk, the maker of weight loss drug Wegovy, will lay off about 9,000 people as it grapples with rising competition in ...

Wall St. provides estimates for future stock prices of Eli Lilly from 2025 to 2030 based on projected revenue and net income.

Big Pharma faces tariff risks, patent cliffs, and regulatory pressure, but innovation and strong pipelines keep Eli Lilly, ...

Lilly, which sells the Alzheimer’s drug Kisunla, has recruited Moore to its global “Brain Health Matters” campaign. Drawing ...

Eli Lilly is inviting early-stage biotechs to make use of drug discovery models that the pharma is providing via a new AI platform. | Eli Lilly is inviting early-stage biotechs to make use of drug ...

Eli Lilly's robust R&D, strong pipeline, and leadership in diabetes, obesity, and oncology underpin its long-term growth ...

In eagerly awaited results from a new study, the pharmaceutical company Eli Lilly reports that a pill its scientists developed causes people who are overweight or obese, but not diabetic, to lose ...

Eli Lilly dominates obesity and diabetes treatments with soaring tirzepatide sales and promising oral drug data. Find out why ...

Eli Lilly's new TuneLab platform gives biotech firms AI-powered drug discovery tools using $1 billion of proprietary research ...

Eli Lilly's retatrutide is still in clinical trials. But gym bros are already using a version of the weight-loss drug, amid a ...

New data from Eli Lilly says its daily, oral GLP-1 pill may help people who have obesity and people who have Type 2 diabetes lose a significant amount of weight.

Circle Pharma, Inc., a clinical-stage biopharmaceutical company, has partnered with Eli Lilly and Company to use Lilly TuneLab, an artificial intelligence and machine learning platform.